[Ambulatory treatment of arterial hypertension urinary the new combination "saluretic and beta-sympatholytic"].
91 hypertensive patients were treated for 8 weeks with a combination of Trasicor80Esidrix. For the first 2 weeks the fixed daily dose was 2 X 80 mg Trasicor and 25 mg Esidrix. From the third week of treatment onwards, the Esidrix dosage was maintained; the dosage of Trasicor 80 was either maintained, increased, or later decreased, according to the results obtained. Following 8 weeks treatment, the systolic blood pressure decreased from 190,4 (+/- 23,0) to 156,0 (+/- 17,7) mmHg, the distolic pressure decreased from 105,9 (+/- 13,5) to 87,6 (+/- 8,3) mmHg. The most marked decrease was recorded after the first week of treatment. In 84% of the cases, the results of the treatment were classed as good and very good; in 11% of cases the treatment was moderately successful, and in 4 patients (5%) the treatment had no effect. The tolerability of Trasicor80Esidrix was remarkably good (in 94% of cases, according to the physician's assessment). 10 patients complained of side effects, and 4 of them discontinued the treatment. Tasicor80Esidrix has been shown to be a safe, simple and practical form of treatment arterial hypertension. It was possible to maintain the selected initial dose of 2 X 80 mg Trasicor and 25 mg Esidrix in 2/3 of the patients.
D055598:Chemical Phenomena; D002621:Chemistry; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010096:Oxprenolol / Q000627:therapeutic use*
D004338:Drug Combinations; D006852:Hydrochlorothiazide; D010096:Oxprenolol
Ambulante Behandlung der arteriellen Hypertonie mit der neuen Kombination "Saluretikum und beta-Sympathikolytikum"